紫杉醇复合顺铂同步放疗盆腔淋巴结阳性Ⅲ期宫颈癌的疗效  

Efficacy of paclitaxel combined with cisplatin in concurrent radiotherapy for pelvic lymph node-positive stage Ⅲ cervical cancer

作　　者：梁业 陈勇 刘小兰 LIANG Ye;CHEN Yong;LIU Xiaolan(Department of Oncology,Xin’gang Central Hospital,Xinyu 338000,China)

机构地区：[1]新钢中心医院肿瘤科,新余338000

出　　处：《上海医药》2022年第7期20-21,71,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:探讨紫杉醇复合顺铂同步放疗盆腔淋巴结阳性Ⅲ期宫颈癌的治疗效果。方法:将80例盆腔淋巴结阳性Ⅲ期宫颈癌患者随机分入对照组和观察组各40例。对照组予以顺铂同步放疗治疗,观察组予以紫杉醇复合顺铂同步放疗治疗。观察两组患者的临床疗效以及发生的不良反应情况。结果:观察组患者的临床疗效,不良反应发生率,随访3年的生存、复发、转移情况优于对照组(均P<0.05)。结论:紫杉醇复合顺铂同步放疗治疗盆腔淋巴结阳性Ⅲ期宫颈癌具有较好的成效,值得临床进一步试验。Objective:To explore the effect of concurrent radiotherapy with paclitaxel and cisplatin for pelvic lymph node-positive stage Ⅲ cervical cancer.Methods:Eighty patients with pelvic lymph node-positive stage Ⅲ cervical cancer were randomly divided into a control group and an observation group with 40 cases each.The control group was treated with concurrent cisplatin radiotherapy while the observation group was treated with paclitaxel combined with cisplatin concurrent radiotherapy.The clinical efficacy and adverse reactions in the two groups were observed.Results:The clinical efficacy,incidence of adverse reactions,survival,recurrence,and metastasis at 3 years of follow-up were better in the observation group than the control group(all P<0.05).Conclusion:Paclitaxel combined with cisplatin for pelvic lymph node-positive stage Ⅲ cervical cancer has good efficacy and is worthy of clinically further trial.

关 键 词：紫杉醇 顺铂 放疗 盆腔淋巴结阳性Ⅲ期宫颈癌 治疗效果 

分 类 号：R979.19[医药卫生—药品] R737.33[医药卫生—药学]